Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution

For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Calligaris, Matteo, Cuffaro, Doretta, Bonelli, Simone, Spanò, Donatella Pia, Rossello, Armando, Nuti, Elisa, Scilabra, Simone Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916773/
https://www.ncbi.nlm.nih.gov/pubmed/33579029
http://dx.doi.org/10.3390/molecules26040944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916773/
https://www.ncbi.nlm.nih.gov/pubmed/33579029
http://dx.doi.org/10.3390/molecules26040944

Ejemplares similares